Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

Abstract Chemotherapy resistance is the main impediment in the treatment of acute myeloid leukaemia (AML). Despite rapid advances, the various mechanisms inducing resistance development remain to be defined in detail. Here we report that loss-of-function mutations (LOF) in the histone methyltransfer...

Full description

Bibliographic Details
Main Authors: Julia M. Kempf, Sabrina Weser, Michael D. Bartoschek, Klaus H. Metzeler, Binje Vick, Tobias Herold, Kerstin Völse, Raphael Mattes, Manuela Scholz, Lucas E. Wange, Moreno Festini, Enes Ugur, Maike Roas, Oliver Weigert, Sebastian Bultmann, Heinrich Leonhardt, Gunnar Schotta, Wolfgang Hiddemann, Irmela Jeremias, Karsten Spiekermann
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84708-6

Internet

https://doi.org/10.1038/s41598-021-84708-6

Similar Items